Cellectis S.A. Sponsored ADR CLLS 深 滬
等待開盤 01-28 09:30:00 美东时间
4.23
+0.150
+3.68%
華盛通- 最 高4.275
- 今 開4.12
- 成交量 2.16万股
- 最 低 4.12
- 昨 收 4.08
- 總市值 4.23亿
- 52周最高 5.4796
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 1.10
- 委 比 -85.26%
- 總股本 10000.00万
- 歷史最高 50.00
- 量 比 0.62
- 振 幅 3.80%
- 歷史最低 0.9628
- 每 手 1
- 風險率 1.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cellectis Announces 2026 Strategy and Catalysts
Cellectis outlines its 2026 strategic priorities, focusing on advancing allogeneic CAR-T therapies. Key catalysts include interim data for lasme-cel in r/r B-ALL from the pivotal Phase 2 BALLI-01 trial, Phase 1 data for eti-cel in r/r NHL, and leveraging partnerships with AstraZeneca, Servier/Allogene, and Iovance. Lasme-cel Phase 1 results show 68% ORR and favorable safety, while eti-cel demonstrates 88% ORR in Phase 1. The company expects to pr...
01-08 21:30
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
Allogene Therapeutics highlights 2026 as pivotal for allogeneic CAR T, with key milestones including interim results for cema-cel in LBCL and proof-of-concept data for ALLO-329 in autoimmune diseases. The company aims to scale CAR T therapy for broader access and real-world use, with a cash runway extending into 2H 2027.
01-08 13:30
Monthly information on share capital and company voting rights
As of December 31, 2025, Cellectis reported a total of 100,339,441 shares in its capital and 105,576,356 total voting rights. For further details, contact the media or investor relations teams, or download the attached document.
01-05 21:30
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.
2025-12-17 02:09
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
2025-12-16 21:06
Cellectis Announces Arbitral Decision in Dispute with Servier
Cellectis announced that the Arbitral Tribunal has partially terminated the License Agreement with Servier regarding UCART19 V1 (ALLO-501), requiring Cellectis to engage in good-faith discussions for a direct license at Allogene's request. All other claims were dismissed. Cellectis is a biotechnology company developing cell and gene therapies using its gene-editing platform. More information is available on their website.
2025-12-15 21:51
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Cellectis presented encouraging updated data from its Phase 1 NATHALI-01 trial for eti-cel, an allogeneic dual CAR-T therapy targeting CD20 and CD22. In patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL) following ≥2 prior therapies, eti-cel achieved an 88% overall response rate (ORR) and 63% complete response (CR) at the current dose level. Preclinical data suggest that low-dose IL-2 administration may enhance CAR-T cell expansion ...
2025-12-08 06:30
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
The latest announcement is out from Cellectis SA ( ($CLLS) ). On December 5, 20...
2025-12-06 05:28
Monthly information on share capital and company voting rights
On November 30, 2025, Cellectis reported a total of 100,325,454 shares and 105,406,812 voting rights. For further details, contact Pascalyne Wilson via media@cellectis.com or Arthur Stril via investors@cellectis.com.
2025-12-03 21:30
